Table 3.
Genetically modified mouse models for ovarian cancer research.
| Genotype(s) | Postulated Tissue of Tumor Origin | Histology of The Tumors | References |
|---|---|---|---|
|
(p53−/−;cMyc+;Kras+)
(p53−/−;Kras+;Akt+) (p53−/−;Akt+;cMyc+) (p53−/−;Akt+;cMyc+;Kras+) |
OSE | primary tumors: poorly differentiated carcinomas; metastasis: poorly differentiated carcinomas and papillary serous carcinomas |
Orsulic et al. (2002) [67] |
| (p53−/−;pRb−/−) | OSE | poorly differentiated carcinomas; | Connolly et al. (2003) [74] |
|
(Hoxa9+)
(Hoxa10+) (Hoxa11+) |
OSE |
Hoxa9+: papillary serous carcinomas; Hoxa10+: endometrioid carcinomas; Hoxa11+: mucinous carcinomas |
Cheng et al. (2005) [79] |
| (Kras+;Pten−/−) | OSE | endometrioid carcinomas | Dinulescu et al. (2005) [65] |
| (Brca1−/−;p53−/−;cMyc+) | OSE | papillary serous carcinomas | Xing and Orsulic (2006) [69] |
| (Apc−/−;Pten −/−) | OSE | endometrioid carcinomas | Wu et al. (2007) [78] |
|
(p53−/−)
(Brca1−/−;p53−/−) (pRb−/−;p53−/−) (pRb−/−;p53−/−;Brca1−/−) |
OSE | malignant leiomyosarcomas | Clark-Knowles et al. (2009) [80] |
| (K-ras−/−;Pten−) | OSE | low-grade serous carcinomas (LGSC) | Fan et al. (2009) [81] |
| (Brca1−/−;p53−/−) | OSE | high-grade leiomyosarcomas | Quinn et al. (2009) [82] |
| (Dicer−/−;Pten −/−) | FTE | high-grade serous carcinomas (HGSC) | Kim et al. (2012) [72] |
|
(Brca1−/−;p53 −/−;pRb−/−)
(Brca2−/−;p53−/−;pRb−/−) |
OSE | serous carcinomas | Szabova et al. (2012) [83] |
|
(Brca1−/−;p53mut;Pten−/−)
(Brca1+/−;p53mut;Pten−/−) (Brca2−/−;p53mut;Pten−/−) (Brca2+/−;p53mut;Pten−/−) |
FTE | serous tubal intra-epithelial carcinomas (STIC) | Perets et al. (2013) [73] |
|
(p53−/−)
(pRb−/−) (p53−/−;pRb−/−) |
OSE |
p53−/−: poorly differentiated CK8-positive neoplasms; p53−/−;pRb−/−: well-differentiated serous epithelial neoplasms, poorly differentiated CK8-positive neoplasms, undifferentiated neoplasms |
Flesken-Nikitin et al. (2013) [70] |
| (p53−/−;Top2a+) | FTE | serous tubal intra-epithelial carcinomas (STIC) | Sherman-Baust et al. (2014) [84] |
| (Lkb1−/−;Pten−/−) | OSE | high-grade serous carcinomas (HGSC) | Tanwar et al. (2014) [85] |
|
(Kras+;Pten−/−)
(Muc1+;Kras+;Pten−/−) |
OSE, FTE | endometrioid carcinomas | Tirodkar et al. (2014) [86] |
| (p53mut;Dicer−;Pten−) | OSE | high-grade serous carcinomas (HGSC) | Kim et al. (2015) [87] |
|
(p53+/+;Pten−/−;Kras+)
(p53+/−;Pten−/−;Kras+) (p53−/−;Pten−/−;Kras+) |
OSE |
p53+/+;Pten−/−;Kras+: low-grade serous carcinomas (LGSC); p53+/−;Pten−/−;Kras+: invasive serous carcinomas, mucinous carcinomas; p53−/−;Pten−/−;Kras+: likely early serous carcinomas |
Ren et al. (2016) [88] |
| (Apc−/−;Pten−/−) | FTE, OSE | OSE: poorly differentiated carcinomas; FTE: well-differentiated tumors |
Wu et al. (2016) [89] |
FTE—fallopian tube epithelium, OSE—ovarian surface epithelium.